Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 May 7;13(1):15.
doi: 10.1186/s13722-018-0116-2.

Stigma associated with medication treatment for young adults with opioid use disorder: a case series

Scott E Hadland  1   2 , Tae Woo Park  3   2 , Sarah M Bagley  4   5   6
Affiliations
Case Reports

Stigma associated with medication treatment for young adults with opioid use disorder: a case series

Scott E Hadland et al. Addict Sci Clin Pract. .

Abstract

Background: Opioid-related overdose deaths have risen sharply among young adults. Despite this increase, access to evidence-based medication for opioid agonist treatment (OAT) for youth remains low. Among older adults, barriers to OAT include the paucity of buprenorphine-waivered prescribers and low rates of prescribing among waivered physicians. We have increasingly found in our clinical practice significant stigma related to using OAT to treat addiction for young adults. In this series, we describe three cases of young adults who faced significant stigma related to their treatment.

Case presentations: The first case is a young male with a history of significant trauma and a severe opioid use disorder. He started buprenorphine and has found a job, stayed abstinent, and began a healthy relationship. At each step in his recovery, he has faced resistance to taking medication from other treatment providers, directors of sober houses, and his parents. The second case is a young woman who presented to a substance use treatment program after a relapse. She was unable to restart buprenorphine despite our calling to ask that it be restarted. Ultimately, she left against medical advice and was stabilized as an outpatient on buprenorphine. The final case is a young woman who stopped buprenorphine after being told she was "not sober" while attending 12-step group but restarted after conversations with her clinical team. In each case, the patient has continued their medication treatment and are stable.

Conclusions: Opioid-related deaths continue to rise among all age groups, including young adults. Stigma related to medication treatment can be a substantial barrier for many young adult patients but there are concrete steps that providers and communities can take to address this stigma.

Keywords: Medication treatment; Stigma; Young adults.

PubMed Disclaimer

References

    1. Rudd R, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–1452. doi: 10.15585/mmwr.mm655051e1. - DOI - PubMed
    1. Committee on Substance Use and Prevention Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138(3):e20161893–e20161893. doi: 10.1542/peds.2016-1893. - DOI - PubMed
    1. Feder KA, Krawczyk N, Saloner B. Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder. J Adolesc Health. 2017;60(6):747–750. doi: 10.1016/j.jadohealth.2016.12.023. - DOI - PMC - PubMed
    1. Hadland SE, Wharam J, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001–2014. JAMA Pediatr. 2017;171(8):747–755. doi: 10.1001/jamapediatrics.2017.0745. - DOI - PMC - PubMed
    1. Walley AY, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393–1398. doi: 10.1007/s11606-008-0686-x. - DOI - PMC - PubMed

Publication types